These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Nussberger J, Gradman AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF. Int J Clin Pract; 2007 Sep; 61(9):1461-8. PubMed ID: 17590217 [Abstract] [Full Text] [Related]
29. Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren. Hong Y, Dingemanse J, Mager DE. Clin Pharmacol Ther; 2008 Jul; 84(1):136-43. PubMed ID: 18288088 [Abstract] [Full Text] [Related]
30. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren. Tapaninen T, Karonen T, Backman JT, Neuvonen PJ, Niemi M. Pharmacogenet Genomics; 2013 Jan; 23(1):19-24. PubMed ID: 23151832 [Abstract] [Full Text] [Related]
31. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. Strasser RH, Puig JG, Farsang C, Croket M, Li J, van Ingen H. J Hum Hypertens; 2007 Oct; 21(10):780-7. PubMed ID: 17541390 [Abstract] [Full Text] [Related]
34. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers. Alkhalidi BA, Tamimi JJ, Salem II, Ibrahim H, Sallam AA. Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838 [Abstract] [Full Text] [Related]
36. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects. Palma-Aguirre JA, Villalpando-Hernández J, Novoa-Heckel G, Oliva I, Cariño L, López-Bojórquez E, Burke-Fraga V, Namur S, González-de la Parra M. Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912 [Abstract] [Full Text] [Related]
37. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP. J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280 [Abstract] [Full Text] [Related]
38. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. Tapaninen T, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651 [Abstract] [Full Text] [Related]